Brief: Bioarctic - EC Refers Lecanemab Marketing Authorisation Decision To Appeal Committee
01/04/2025 11:20
April 1 (Reuters) - BioArctic AB BIOAb.ST: EC REFERS LECANEMAB MARKETING AUTHORISATION DECISION TO APPEAL COMMITTEE Source text: ID:nWkr8ywVZh Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln